Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUG2 trials

Sponsors

Gilead Sciences Inc., Xencor Inc.

Conditions

Advanced Non-Small Cell Lung CancerAdvanced Non-small Cell Lung Cancer

Phase 1

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

CompletedCTIS2023-509644-10-00

Xencor Inc.Advanced Non-small Cell Lung Cancer

Start: 2024-06-27End: 2025-12-29Target: 116Updated: 2025-11-17

Phase 2

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruitingCTIS2022-502916-35-01

Gilead Sciences Inc.Advanced Non-Small Cell Lung Cancer

Start: 2024-03-27Target: 171Updated: 2025-09-10